AOD-9604 (HGH Fragment 177-191): Lipolysis Without Growth Hormone Effects

What AOD-9604 Is

AOD-9604 is a synthetic modified peptide based on the C-terminal fragment of human growth hormone (hGH) — specifically amino acids 177 through 191 of the full hGH molecule. The “AOD” stands for “anti-obesity drug” — a naming choice that reflects the compound’s development orientation toward fat loss applications.

The design rationale was elegant: full human growth hormone produces complex systemic effects, many of which are undesirable in a fat loss context (insulin resistance, tissue growth effects, IGF-1 elevation). A fragment containing just the lipolytic region of hGH could, in principle, produce the fat loss benefit without the full hormonal cascade.

The Mechanism

AOD-9604’s proposed mechanism of action:

• Direct stimulation of lipolysis in adipocytes, mimicking the lipolytic effect of full hGH
• Inhibition of lipogenesis — reducing new fat deposition
• Minimal effect on circulating IGF-1 — unlike full hGH
• Minimal insulin resistance effects — a feature that distinguishes AOD-9604 from full hGH administration
• No significant effect on growth hormone release — operates as a standalone fat loss mechanism

Clinical Development History

AOD-9604 has an unusual development history. It was studied in phase 2 clinical trials for obesity in the 2000s. Results were mixed — some studies showed modest weight loss, others were less compelling. Commercial drug development did not advance the compound to a pharmaceutical approval. The compound subsequently entered the compounding-pharmacy and research-peptide space, where it has been used in physician-supervised practice.

What the Research Actually Shows

Published research on AOD-9604 describes:

• Modest body fat reduction in preclinical and early clinical settings
• Reduced triglycerides in some studies
• Minimal effect on IGF-1 — confirmed across the clinical dataset
• Good tolerability — adverse event rates in the phase 2 obesity trials were comparable to placebo
• Variable weight loss — some patients respond better than others, consistent with many metabolic interventions

The effect size in phase 2 obesity trials was modest — typically in the range of a few pounds over the study period. This did not meet the commercial bar for drug approval, but is consistent with a useful adjunctive option for appropriately selected patients.

Where AOD-9604 Fits in Clinical Practice

In physician-supervised practice, AOD-9604 has typically been considered for:

• Fat loss adjunct alongside lifestyle intervention
• [Body composition optimization](https://newtropin.com/blog/growth-hormone-peptides-for-fat-loss/) in patients already pursuing multiple strategies
• GH-like lipolytic effects in patients where full GH axis intervention is undesirable
• Combined protocols alongside other peptides

It is not positioned as a primary weight loss therapy — GLP-1 class compounds have substantially more evidence and larger effect sizes.

Regulatory Status

AOD-9604 is not FDA-approved as a commercial pharmaceutical. Clinical access has depended on the 503A compounding pharmacy framework, subject to ongoing PCAC review. Current status should be verified against the most recent FDA record.

Dosing Considerations

AOD-9604 has typically been administered:

• Subcutaneously
• In the low-milligram daily range
• Often pre-bedtime, consistent with endogenous GH circadian patterns
• In 8–12 week protocols

Specific dosing depends on compounding pharmacy formulation.

Key Takeaways

• AOD-9604 is a synthetic fragment of hGH covering amino acids 177–191.
• The design rationale was lipolytic effect without full GH hormonal cascade.
• Phase 2 obesity trials showed modest but real effects; commercial development did not advance.
• IGF-1 levels are not meaningfully affected — a distinguishing feature from full hGH.
• Clinical role is as an adjunct rather than primary therapy.
• Regulatory access depends on the 503A framework; current verification required.

Frequently Asked Questions

What is AOD-9604 used for?

It is used as an adjunctive fat loss intervention in physician-supervised practice, based on its lipolytic and anti-lipogenic effects.

Does AOD-9604 raise IGF-1?

No — one of the distinguishing features of AOD-9604 versus full hGH is that it does not meaningfully elevate IGF-1.

How much weight loss can I expect with AOD-9604?

Effects are typically modest — a few pounds of body fat reduction over an 8–12 week protocol, often less pronounced than GLP-1-class interventions.

Is AOD-9604 FDA-approved?

No. Clinical access has depended on 503A compounding.